Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$75,347,506
New position
Shares Held
382,048
first reported quarter
Ownership
0.025%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$1,824,285
CallShares
9,250
PutValue
$1,153,737
PutShares
5,850
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Qube Research & Technologies Ltd holds $1,093,630,705 across 9 Drug Manufacturers - General names. AZN ranks #3 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
715,082 | $657,710,971 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
3,203,665 | $194,302,282 | |
| 3 | AZN |
Astrazeneca PLC
This page
|
382,048 | $75,347,506 | |
| 4 | AMGN |
Amgen Inc
|
147,488 | $51,893,652 | |
| 5 | BIIB |
Biogen Inc.
|
212,921 | $39,034,806 | |
| 6 | GSK |
GSK plc
|
548,222 | $30,256,372 | |
| 7 | NVS |
Novartis AG
|
173,137 | $26,446,676 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
121,052 | $16,871,017 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,824,285 | 9,250 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $1,153,737 | 5,850 | Put | Sole | 2026-05-15 | |
| 2026-03-31 | $75,347,506 | 382,048 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||